Fig. 4

Changes in Cth affect intestinal barrier repair, and the mechanism is dependent on the ERK1/2 pathway in vivo. A Bar graphs showing changes in intestinal barrier indicators (D-LA, IFABP), inflammatory factors (IL-6, TNF-α) and anti-inflammatory repair indicators (IL-10, Lipoxin A4, RvD1, RvE1) following alterations in the Cth and ERK1/2 pathways. n = 6/group. ***P ≤ 0.001, ****P ≤ 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. B Representative H&E staining images showing changes in intestinal mucosal morphology after alterations in the Cth and ERK1/2 pathways (scale = 50 μm). Sham: sham-operated group; I/R: I/R group; I/R + PAG: I/R model mice were administered the Cth inhibitor propargylglycine (PAG); I/R + MCH: I/R were administered the Cth agonist methacholine (MCH); I/R + MCH + PD: I/R model mice were administered the Cth agonist MCH and the ERK1/2 inhibitor PD98059 (PD); I/R + PAG + PMA: I/R model mice were administered the Cth inhibitor PAG and the ERK1/2 agonist PMA